Merck & Co. (MRK)

Total return at 5 years: -1.8%/year = -4.8% appreciation + 3.0% dividend. The target price ($114) is ex-dividend; the $20 in dividends collected over 5 years are added separately.

The methods disagree: one places the value today above the price ($145) and the other below.

Today — expensive, no margin of safety: at $145 trades ~33.8% above its value discounted to today (~$109); the expected return does not even reach the risk-free rate (4.5%).

At 5 years — Sobrevalorado: the expected total return is negative — the price already discounts a demanding scenario that, if not met, results in a loss.

The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$70.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($145) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (-6.3%/year) than we project (2.0%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$15.7 bn of owner earnings in year 5 (vs ~$24 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Rolling grid: year 0 is the real TTM (revenue of US$66.6 billion as of Jun 30, 2026). Merck is an oncology pharmaceutical company: Keytruda (anti-PD-1) was 49% of 2025 sales ($31.7bn). It is valued at the enterprise level, on an adjusted basis (~$8.8/share normalized), neither GAAP nor Merck's own non-GAAP ($8.98 in 2025 but −$1.28 in Q1'26): both are distorted by the acquired IPR&D charges from the M&A wave (Cidara $3.62/share + Terns $2.35/share), which Merck runs through non-GAAP and which sink FY26 guidance to $5.04-5.16. Normalized earnings add back those one-off charges + intangible amortization (non-economic). ⭐ The model models the Keytruda cliff (§2, not constant growth): earnings grow toward ~2028, then the US biosimilar (Dec-2028) + IRA government pricing (Jan-2029) erode Keytruda, offset by subcutaneous Keytruda (Qlex), WINREVAIR (+88%), Capvaxive, the Daiichi ADCs and Animal Health → earnings stay roughly flat over five years. Exit multiple 14× = the floor of the pharma band [14,22] (a discount for the cliff). The stock's rise has already discounted a successful transition; the return comes down to the dividend (2.7%) + modest growth. Net debt of ~$43bn (up with the M&A) enters the bridge: the multiple goes on adjusted after-tax operating income, which is pre-interest, so the funding is charged only once. Update to the quarter ended 30 June 2026: trailing-twelve-month revenue grew 4.6% year over year (65.8 to 66.6 billion dollars), above the 1.9% the model's first year assumed. The quarterly pace was stable and accelerating —3.7% in the quarter ended September 2025, 5.0% in December, 4.9% in March 2026 and 5.1% in June—, with no easy comparison or one-off event to explain the difference against the projected path. The model's first year is therefore raised to that pace (4.6%) and made to decay smoothly toward the plateau that already preceded the expiry of Keytruda exclusivity in December 2028, leaving the decline and recovery already modeled for years three and four untouched. Reported net income for the same period fell to a 4.8% margin on revenue, well below the 33% the model uses. The cause is the same acquired research and development charge that already distorted the first quarter of 2026 (Cidara and Terns): the quarterly levels reported to the Securities and Exchange Commission show negative net income in both the first and second quarters of 2026. Operating income and operating cash flow for the period do not take that charge —the base-year operating cash flow margin rises slightly, to 30.0% from 27.2%—, so the normalized adjusted earnings (a 33% margin) on which the valuation runs are unchanged.

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $114 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $145, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $114 in 5 years plus $20 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $109. Against the current market price ($145), the margin of safety is -33.8% (trades above the maximum → a premium is paid) and the total return at that price would be -1.8% annually.

• Multiple vs the band. EV/NOPAT ~19× the normalized result, against the floor of the pharma band (14-22×) given the cliff — not the ~25× that guidance distorted by M&A charges implies.
• The 2026 re-rating. The stock rose as visibility into the transition improved. The margin has compressed; the panic has passed.
• Margin of safety. 5y base ~$114 vs price ~$145 → total return -2%/year (the dividend 2.7% of it, most of the total). A thin margin; a bet on executing the transition, not a bargain.

• ✓ ROIC exceeds the cost of capital (~10%)
• ✓ High incremental ROIC (compounding)
• ✓ CFROIC backs up the ROIC (105%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• ROIC vs the 10% bar. ROIC ~20% — well above the bar (the oncology franchise carries a very high margin; M&A dilutes it). Genuine quality in the underlying business.
• Quality of cash. TTM free cash flow (~$16bn) is solid. ⚠️ Reported earnings (GAAP and non-GAAP) are distorted by M&A-related IPR&D charges — they need to be normalized.
• Post-M&A balance sheet. Net debt ~$43bn (from near-neutral) on the M&A wave; investment grade, ample coverage. More leveraged than the historical norm.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

Merck's engine is Keytruda (49% of sales, +7%), and everything revolves around defending/replacing it before the U.S. patent cliff (Dec-2028). The defense: subcutaneous Keytruda (Qlex, a 30-40% retention target), WINREVAIR (+88%, on track to blockbuster), Capvaxive, the Daiichi ADCs (three candidates with breakthrough-therapy designation) and >$60bn of M&A since 2021. The drags: Gardasil (HPV) collapsed on China ($0 of shipments), the diabetes franchise is expired, and Januvia/Bridion lose exclusivity in 2026. The dividend (2.7%, raised +4.9%) + a modest buyback (~$3bn/year) return cash; the bulk of capital goes to the pipeline (R&D $15.8bn + M&A).

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Real, not nominal. Keytruda's (+7%) and WINREVAIR's (+88%) growth is real; but the consolidated figure (+1%) is diluted by Gardasil (China) + off-patent diabetes.
• Growth engine. The pipeline (Qlex + WINREVAIR + Capvaxive + Daiichi ADCs) — whether it offsets/exceeds the Keytruda patent cliff. The central unknown.
• The cliff. The Keytruda biosimilar (Dec-2028) + IRA pricing (Jan-2029) are the negative inflection point; the model flattens earnings over five years. The large binary risk.

• Relevant in 10 years (recurrence). Oncology (Keytruda) + vaccines + Animal Health are critical, recurring healthcare. But Keytruda (49%) faces the cliff — post-2028 recurrence depends on the pipeline.
• Pricing power. Strong while the patent lasts (Keytruda, exclusive vaccines); but government IRA pricing and biosimilars erode it post-2028. Gardasil showed fragility (China).
• Moat and its direction. Wide moat but with scheduled erosion (Keytruda's patent falls 2028-2029); the direction depends on whether the pipeline + Qlex rebuild it. The central disconfirmer.
• Concentration in Keytruda. 49% of sales in a single product with a cliff on the horizon is an extreme concentration — the largest structural vulnerability.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $0 bn
• ✓Interest coverage (EBIT / interest)13.8x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 105% of ROIC
• ✓Value creation (ROIC − 10% bar)+10pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 0.7x — no over-investment
• !Float / working capitalConsumes cash $1 bn (positive WC)
• ✓Dilution (SBC % of revenue + shares)SBC 1.3% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Leverage. Net debt ~$43bn after the M&A (was near-neutral); investment grade, ample coverage. Manageable, more leveraged than the norm.
• Cash generation. TTM free cash flow ~$16bn; covers the dividend (~$8.2bn) + the buyback. Stock-based compensation is small (~$0.9bn). The IPR&D charges consume cash but represent the investment in the pipeline.
• Dividend sustainability. Free cash flow covers the dividend (2.7%, raised +4.9%). Solid, though the cliff pressures the future earnings that back it.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• Skin in the game. Davis holds 1.23M shares + options; dispersed ownership (no founder control). Executed >$60bn of M&A for the pipeline. Reasonable alignment.
• Capital allocation. Reinvestment-first (R&D + M&A) to rebuild the pipeline before the cliff — the right bet if it delivers. Dividend + modest buyback. M&A distorts earnings (IPR&D charges).
• Execution / integrity. Execution of the post-Keytruda transition is the test. ⚠️ The Gardasil/China securities lawsuit (alleging investors were misled about demand) is a blemish to watch.

• It appears expensive at ~25× FY2026 guidance ($5.04-5.16), but that guidance is depressed by acquired-IPR&D charges from M&A (Cidara $3.62/share, Terns $2.35/share) that Merck runs through its non-GAAP; on normalized earnings (~$8.8/share) it trades at ~19×, the pharma floor.
• The Keytruda patent cliff (49% of sales, biosimilar Dec-2028) is a real, structural fear — but the market has already started re-rating the stock as visibility into the transition (Qlex, WINREVAIR, pipeline) improved.
• The collapse of Gardasil in China ($0 of shipments) plus the value-stock demand added bearish noise — a real headwind, but confined to ~8% of sales.

Merck is a two-layer case. First: it is not as expensive as it looks — guidance distorted by M&A charges hides that it trades at ~19× normalized earnings (the floor of the pharma band). Second: but neither is it a bargain — the re-rating already happened, and at 19× the market is discounting that the pipeline offsets the Keytruda cliff. The perception-reality gap has largely closed: the 2025 panic (China + the cliff) gave way to the 'visibility of the transition' of 2026. What remains is a bet on execution — if Qlex retains and the pipeline delivers, there is upside; if the cliff dominates (as with Pfizer/Bristol Myers), there is downside. It is not a bargain with a wide margin, but a quality business at a reasonable price with a large binary risk.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at -12%/year (-49% total): the margin of safety protects the downside. The bull (+4%/year, +23% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Keytruda patent cliff. The central disconfirmer: 49% of sales, biosimilar Dec-2028 + IRA pricing Jan-2029; if the pipeline fails to replace it, earnings decline as with Pfizer/Bristol Myers.
• Pipeline dependence. Replacing 49% of sales is historically very difficult; the pipeline could fail or arrive late. Merck flags this as an explicit risk.
• Gardasil/China + litigation. Shipments to China are at $0 (structural collapse); a securities lawsuit alleges Merck misled investors about that demand. A real but limited drag, confined to ~8% of sales.
• Debt + M&A charges. Net debt ~$43bn; acquired-IPR&D charges distort earnings and consume cash, with no guarantee that the purchased pipeline will deliver returns.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: wide moat, eroding.

• Peter Lynch Growth at a reasonable price (GARP)

  A slow grower growing 2% at a multiple/growth of 9.7 → expensive for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 7% (EBIT/EV) + ROIC 20% → brushes the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts -6% vs our 2%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor -16%/yr over 5y (material loss) → risk of permanent capital loss.

• Pat Dorsey Moat strength (Five Rules)

  A wide moat, eroding; sources: intangibles, efficient scale, switching costs → partially passes the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting -6%, within what we project (2%) — the story squares with the numbers.